Symbols / SCNI
SCNI Chart
About
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.74M |
| Enterprise Value | 5.21B | Income | 347.00K | Sales | 1.15M |
| Book/sh | 1.47 | Cash/sh | 989000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31 | IPO | — |
| P/E | 0.21 | Forward P/E | — | PEG | — |
| P/S | 2.39 | P/B | 0.58 | P/C | — |
| EV/EBITDA | -772.37 | EV/Sales | 4541.97 | Quick Ratio | 0.53 |
| Current Ratio | 0.71 | Debt/Eq | 29.98 | LT Debt/Eq | — |
| EPS (ttm) | 4.00 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 36.10% | Earnings | 2024-05-15 16:00 | ROA | -39.55% |
| ROE | 17.92% | ROIC | — | Gross Margin | -146.99% |
| Oper. Margin | -4.87% | Profit Margin | 4.48% | Shs Outstand | 3.19M |
| Shs Float | 5.35B | Short Float | 1.51% | Short Ratio | 0.92 |
| Short Interest | — | 52W High | 6.18 | 52W Low | 0.61 |
| Beta | 1.89 | Avg Volume | 48.94K | Volume | 43.76K |
| Target Price | — | Recom | None | Prev Close | $0.73 |
| Price | $0.86 | Change | 17.67% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.86
Latest analyst target
3. DCF / Fair value
$-19.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.86
Low
—
High
—
Mean
—
- Scinai takes Recipharm Israel site to build end-to-end drug manufacturing path - Stock Titan ue, 17 Feb 2026 12
- Scinai Immunotherapeutics Buys Recipharm Israel Unit, Seals Strategic CDMO Pact - TipRanks ue, 17 Feb 2026 14
- Major Breakthrough: Scinai Clears Critical Hurdle in €12M Rare Disease Drug Acquisition Deal - Stock Titan hu, 05 Jun 2025 07
- There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability - Yahoo Finance Fri, 29 Nov 2024 08
- SCNI Stock Touches 52-Week Low at $2.18 Amid Market Challenges - Investing.com UK Wed, 09 Apr 2025 07
- Geopolitics Watch: Will Inhibrx Biosciences Inc stock recover after earnings - Weekly Investment Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn Fri, 13 Feb 2026 13
- Can NOEMR stock double in the next year - Global Markets & Intraday High Probability Alerts - mfd.ru Fri, 20 Feb 2026 21
- PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition - InvestorPlace Mon, 15 Jul 2024 07
- SCNI - Scinai Immunotherapeutics Ltd. Latest Stock News & Market Updates - Stock Titan Mon, 11 Sep 2023 11
- How geopolitical tensions affect Earlyworks Co. Ltd Depositary Receipt stock - Weekly Gains Summary & Real-Time Volume Surge Alerts - mfd.ru ue, 17 Feb 2026 17
- Gift chain with Stamford, Norwalk stores declares bankruptcy - Stamford Advocate ue, 14 Jul 2020 07
- Why Is Kaival Brands Innovations (KAVL) Stock Down 33% Today? - InvestorPlace Mon, 17 Jun 2024 07
- Can RORO stock attract ESG investments - 2025 EndofYear Setup & Fast Gain Swing Alerts - mfd.ru Sun, 15 Feb 2026 13
- Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - PR Newswire ue, 02 Sep 2025 07
- Why Is AMC Networks (AMCX) Stock Down 11% Today? - InvestorPlace Mon, 17 Jun 2024 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 3.40M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.23 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.90M | -5.28M | -7.47M | -9.90M |
| TotalUnusualItems | 14.77M | 3.09M | 2.23M | -487.00K |
| TotalUnusualItemsExcludingGoodwill | 14.77M | 3.09M | 2.23M | -487.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 4.80M | -6.50M | -5.80M | -8.21M |
| ReconciledDepreciation | 1.65M | 514.00K | 562.00K | 471.00K |
| ReconciledCostOfRevenue | 1.24M | 0.00 | 0.00 | |
| EBITDA | 7.87M | -2.19M | -5.23M | -10.39M |
| EBIT | 6.22M | -2.70M | -5.80M | -10.86M |
| NetInterestIncome | -1.33M | 115.00K | 3.03M | 3.14M |
| InterestExpense | 1.42M | 3.80M | 0.00 | 3.49M |
| InterestIncome | 100.00K | 3.92M | 3.05M | 3.15M |
| NormalizedIncome | -6.57M | -9.59M | -8.03M | -7.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 4.80M | -6.50M | -5.80M | -8.21M |
| TotalExpenses | 9.30M | 9.71M | 11.06M | 10.86M |
| RentExpenseSupplemental | 101.05K | |||
| TotalOperatingIncomeAsReported | -8.64M | -9.71M | -11.06M | -10.86M |
| DilutedAverageShares | 806.37K | 390.66K | 188.52K | 141.14K |
| BasicAverageShares | 806.37K | 390.66K | 188.52K | 141.14K |
| DilutedEPS | 0.00 | -16.00 | -40.00 | -80.00 |
| BasicEPS | 0.00 | -16.00 | -40.00 | -80.00 |
| DilutedNIAvailtoComStockholders | 0.00 | -6.50M | -5.80M | -8.21M |
| NetIncomeCommonStockholders | 0.00 | -6.50M | -5.80M | -8.21M |
| PreferredStockDividends | 4.80M | |||
| NetIncome | 4.80M | -6.50M | -5.80M | -8.21M |
| NetIncomeIncludingNoncontrollingInterests | 4.80M | -6.50M | -5.80M | -8.21M |
| NetIncomeContinuousOperations | 4.80M | -6.50M | -5.80M | -8.21M |
| PretaxIncome | 4.80M | -6.50M | -5.80M | -8.21M |
| OtherIncomeExpense | 14.77M | 3.09M | 2.23M | -487.00K |
| SpecialIncomeCharges | 14.76M | 0.00 | 0.00 | |
| OtherSpecialCharges | -14.76M | |||
| GainOnSaleOfSecurity | 7.00K | 3.09M | 2.23M | -487.00K |
| NetNonOperatingInterestIncomeExpense | -1.33M | 115.00K | 3.03M | 3.14M |
| TotalOtherFinanceCost | 10.00K | 8.00K | 21.00K | 9.00K |
| InterestExpenseNonOperating | 1.42M | 3.80M | 0.00 | 3.49M |
| InterestIncomeNonOperating | 100.00K | 3.92M | 3.05M | 3.15M |
| OperatingIncome | -8.64M | -9.71M | -11.06M | -10.86M |
| OperatingExpense | 8.06M | 9.71M | 11.06M | 10.86M |
| OtherOperatingExpenses | -9.00K | -12.00K | ||
| DepreciationAmortizationDepletionIncomeStatement | 176.68K | |||
| DepreciationAndAmortizationInIncomeStatement | 176.68K | |||
| DepreciationIncomeStatement | 176.68K | |||
| ResearchAndDevelopment | 5.53M | 5.21M | 5.76M | 3.25M |
| SellingGeneralAndAdministration | 2.53M | 4.50M | 5.30M | 7.62M |
| GeneralAndAdministrativeExpense | 7.72M | |||
| OtherGandA | 2.71M | |||
| RentAndLandingFees | 101.05K | |||
| SalariesAndWages | 4.90M | |||
| GrossProfit | -580.00K | 0.00 | 0.00 | |
| CostOfRevenue | 1.24M | 0.00 | 0.00 | |
| TotalRevenue | 658.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 658.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.41B | 1.86B | 989.29M | 739.05M |
| ShareIssued | 3.41B | 1.86B | 989.29M | 739.05M |
| NetDebt | 14.50M | 6.01M | 9.79M | |
| TotalDebt | 2.09M | 20.56M | 21.54M | 28.98M |
| TangibleBookValue | 4.35M | -4.57M | -1.76M | 982.00K |
| InvestedCapital | 4.61M | 14.80M | 18.32M | 28.15M |
| WorkingCapital | 585.00K | 3.67M | 12.03M | 15.40M |
| NetTangibleAssets | 9.98M | -4.57M | -1.76M | 982.00K |
| CapitalLeaseObligations | 1.83M | 1.19M | 1.46M | 1.82M |
| CommonStockEquity | 4.35M | -4.57M | -1.76M | 982.00K |
| PreferredStockEquity | 5.63M | |||
| TotalCapitalization | 10.24M | 14.80M | 18.32M | 28.15M |
| TotalEquityGrossMinorityInterest | 9.98M | -4.57M | -1.76M | 982.00K |
| StockholdersEquity | 9.98M | -4.57M | -1.76M | 982.00K |
| GainsLossesNotAffectingRetainedEarnings | -1.74M | -1.74M | -2.01M | -2.06M |
| OtherEquityAdjustments | -1.74M | -1.74M | -2.01M | -2.06M |
| RetainedEarnings | -117.54M | -122.33M | -115.83M | -110.04M |
| AdditionalPaidInCapital | 123.63M | 119.51M | 116.08M | 113.08M |
| CapitalStock | 5.63M | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 5.63M | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 3.47M | 22.04M | 28.83M | 31.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.67M | 20.26M | 26.49M | 28.61M |
| DerivativeProductLiabilities | 3.00K | 96.00K | 5.33M | 0.00 |
| EmployeeBenefits | 95.00K | |||
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 95.00K | |||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.66M | 20.16M | 21.16M | 28.61M |
| LongTermCapitalLeaseObligation | 1.40M | 797.00K | 1.08M | 1.45M |
| LongTermDebt | 260.00K | 19.37M | 20.08M | 27.16M |
| CurrentLiabilities | 1.81M | 1.78M | 2.34M | 2.44M |
| CurrentDeferredLiabilities | 225.00K | 0.00 | ||
| CurrentDeferredRevenue | 225.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 424.00K | 396.00K | 382.00K | 375.00K |
| CurrentCapitalLeaseObligation | 424.00K | 396.00K | 382.00K | 375.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 484.00K | 709.00K | ||
| PayablesAndAccruedExpenses | 1.16M | 1.38M | 1.96M | 2.07M |
| CurrentAccruedExpenses | 781.00K | 849.00K | 1.24M | 1.07M |
| Payables | 376.00K | 535.00K | 716.00K | 999.00K |
| AccountsPayable | 376.00K | 535.00K | 716.00K | 999.00K |
| TotalAssets | 13.45M | 17.47M | 27.07M | 32.04M |
| TotalNonCurrentAssets | 11.06M | 12.03M | 12.70M | 14.19M |
| OtherNonCurrentAssets | 444.00K | |||
| NetPPE | 11.06M | 12.03M | 12.70M | 14.19M |
| AccumulatedDepreciation | -4.46M | -2.81M | -2.42M | -2.13M |
| GrossPPE | 15.51M | 14.83M | 15.12M | 16.32M |
| Leases | 3.72M | 3.72M | 3.92M | 4.43M |
| ConstructionInProgress | 0.00 | 7.45M | 7.83M | 8.86M |
| OtherProperties | 4.02M | 3.34M | 3.04M | 2.69M |
| MachineryFurnitureEquipment | 7.77M | 321.00K | 332.00K | 339.00K |
| BuildingsAndImprovements | 7.83M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.39M | 5.45M | 14.37M | 17.84M |
| RestrictedCash | 131.00K | 140.00K | 140.00K | 143.00K |
| PrepaidAssets | 79.00K | 71.00K | 45.00K | 228.00K |
| Receivables | 217.00K | 366.00K | 110.00K | 98.00K |
| OtherReceivables | 134.00K | 366.00K | 110.00K | 98.00K |
| AccountsReceivable | 83.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 1.96M | 4.87M | 14.07M | 17.37M |
| CashAndCashEquivalents | 1.96M | 4.87M | 14.07M | 17.37M |
| CashFinancial | 54.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.35M | -10.02M | -8.10M | -7.57M |
| RepaymentOfDebt | -392.62K | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 2.00M | 139.00K | 932.00K | 21.43M |
| CapitalExpenditure | -12.00K | -637.00K | -836.00K | -139.00K |
| InterestPaidSupplementalData | 143.00K | 833.00K | 916.00K | 0.00 |
| EndCashPosition | 2.10M | 5.01M | 14.21M | 17.52M |
| BeginningCashPosition | 5.01M | 14.21M | 17.52M | 3.08M |
| EffectOfExchangeRateChanges | -9.00K | -272.00K | -1.98M | 575.00K |
| ChangesInCash | -2.91M | -8.93M | -1.32M | 13.87M |
| FinancingCashFlow | 3.44M | 1.09M | 6.78M | 21.43M |
| CashFlowFromContinuingFinancingActivities | 3.44M | 1.09M | 6.78M | 21.43M |
| ProceedsFromStockOptionExercised | 1.44M | 947.00K | 5.84M | 0.00 |
| NetCommonStockIssuance | 2.00M | 139.00K | 932.00K | 21.43M |
| CommonStockIssuance | 2.00M | 139.00K | 932.00K | 21.43M |
| NetIssuancePaymentsOfDebt | -392.62K | |||
| NetLongTermDebtIssuance | -392.62K | |||
| LongTermDebtPayments | -392.62K | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -12.00K | -637.00K | -836.00K | -139.00K |
| CashFlowFromContinuingInvestingActivities | -12.00K | -637.00K | -836.00K | -139.00K |
| NetOtherInvestingChanges | 9.33K | |||
| NetPPEPurchaseAndSale | -12.00K | -637.00K | -836.00K | -139.00K |
| SaleOfPPE | 12.87K | |||
| PurchaseOfPPE | -12.00K | -637.00K | -836.00K | -139.00K |
| OperatingCashFlow | -6.33M | -9.38M | -7.26M | -7.43M |
| CashFlowFromContinuingOperatingActivities | -6.33M | -9.38M | -7.26M | -7.43M |
| InterestReceivedCFO | 0.00 | |||
| InterestPaidCFO | -10.62K | |||
| ChangeInWorkingCapital | 112.00K | -796.00K | 271.00K | 704.00K |
| ChangeInOtherCurrentLiabilities | -314.00K | -58.00K | -156.00K | -150.00K |
| ChangeInOtherCurrentAssets | 284.00K | 43.00K | 153.00K | 148.00K |
| ChangeInPayablesAndAccruedExpense | 1.00K | -491.00K | 134.00K | 647.00K |
| ChangeInPayable | 1.00K | -491.00K | 134.00K | 647.00K |
| ChangeInAccountPayable | -156.00K | -150.00K | -175.00K | 3.00K |
| ChangeInReceivables | 141.00K | -290.00K | 140.00K | 59.00K |
| ChangesInAccountReceivables | -83.00K | |||
| OtherNonCashItems | -13.48M | 401.00K | -3.90M | -3.15M |
| StockBasedCompensation | 682.00K | 1.14M | 1.60M | 2.76M |
| DepreciationAmortizationDepletion | 1.65M | 514.00K | 562.00K | 471.00K |
| DepreciationAndAmortization | 1.65M | 514.00K | 562.00K | 471.00K |
| Depreciation | 1.65M | 514.00K | 562.00K | 471.00K |
| OperatingGainsLosses | -93.00K | -4.14M | ||
| PensionAndEmployeeBenefitExpense | 0.00 | |||
| GainLossOnInvestmentSecurities | -93.00K | -4.14M | ||
| NetIncomeFromContinuingOperations | 4.80M | -6.50M | -5.80M | -8.21M |
Public Trades for SCNI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|